DOJ Clears Paramount Skydance-Warner Bros. Discovery Merger Without Conditions 
Japan Core Inflation Seen Steady in May Ahead of BOJ Rate Hike 
Wizz Air Beats Profit Forecast as Cost Controls Offset Industry Challenges 
Trump Says Iran Peace Deal Near as Markets Rally and Oil Prices Fall 
EngineAI Files for Hong Kong IPO Amid Rising Demand for AI and Robotics Stocks 
Kremlin Says New EU Sanctions Won’t Hurt Russian Banks 
ECB Set to Raise Interest Rates as Energy Shock Fuels Eurozone Inflation Concerns 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Alibaba Offers $1.5 Billion to Acquire Grocery Delivery Platform Pupu 
Trump Signals Possible U.S.-Iran Peace Deal as Hormuz Reopening Nears 
OpenAI Eyes Massive 10GW Ohio Data Center Campus in Potential $500 Billion AI Infrastructure Deal 
Trump Signals Opposition to USMCA Renewal as U.S. Reviews Trade Relations with Canada and Mexico 
Hanmi Semicon Shares Surge After $33 Million SpaceX Investment 
SpaceX IPO Demand Surges Past $250 Billion Ahead of Historic Market Debut 
Trump Administration Defends Anthropic AI Restrictions in Ongoing Federal Lawsuit 
Gold Prices Slip Weekly Despite Friday Rebound as U.S.-Iran Peace Deal Hopes Grow 
Sigma Healthcare Shares Slide Amid Preliminary Boots Acquisition Talks 
LG Chem Ltd. announced it set to buy AVEO Pharmaceuticals for $566 million or $15 per share in full cash. The South Korean chemical company headquartered in Seoul is aiming to purchase a 100% stake in the Boston-based company.
With the acquisition, LG Chem will expand its commercial footprint in the US market for a wide range of oncology therapies. The company also revealed on Tuesday, Oct. 18, that it will also use the deal to branch out to other related fields.
According to The Korea Times, AVEO Pharma developed FOTIVDA prescription medicine made for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC). this drug was only approved in March 2021 by the U.S. Food and Drug Administration (FDA).
LG Chem said that this is the first time that a South Korean company is buying a firm that has been granted approval by the FDA for a new type of drug. As it acquires AVEO, the company is planning to invest in LG Chem Life Science Innovation Center so it can establish a special purpose company for the takeover of the US-based pharma firm.
Moreover, the deal will provide LG Chem’s Life Sciences unit with a commercial presence in the United States. This will also speed up the company’s efforts to deliver its continued growth.
The transaction is expected to close in early 2023, and as with any other buyout deals, this is still subject to customary closing conditions. It should be approved by AVEO’s shareholders and go through regulatory processes.
“With its track record of clinical success, deep pipeline of innovative therapies and continued growth trajectory following the successful commercialization of FOTIVDA, AVEO is the perfect partner for LG Chem Life Sciences,” LG Chem’s chief executive officer, Shin Hak Cheol, said in a press release. “This transaction represents the next step in our portfolio transformation towards higher growth markets and provides a strong commercial foundation in oncology as we continue to develop our anti-cancer offerings.
The CEO further said, “We remain focused on prudently investing in our R&D capabilities, continuing to build a leading portfolio of therapies and transforming lives through inspiring science and leading innovation.”
